Navigation Links
Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
Date:9/7/2007

BALTIMORE, Sept. 7 /PRNewswire/ -- Alba Therapeutics Corporation today announced the appointment of Betsy Van Parijs, M.D., Ph.D. to Senior Vice President, Clinical Development and Medical Affairs. In this role, Dr. Van Parijs will be responsible for leading Alba's clinical development strategy and program execution through product approval and commercialization. Dr. Van Parijs will also serve as a member of Alba's executive management leadership team.

"We are very pleased to announce that Dr. Van Parijs is joining Alba in this critical leadership role. Betsy is an accomplished executive with extensive experience in clinical development including the development, execution and validation of a patient-reported outcomes (PRO) instrument as a new primary efficacy endpoint for clinical trials," said Blake Paterson, M.D., Alba's Chief Executive Officer. "Her leadership in our efforts to validate the celiac disease activity rating score in our upcoming Phase II clinical trials will be essential for the success of AT-1001 as the first drug for celiac disease," added Dr. Paterson.

"Alba has a singular approach to the treatment of seemingly diverse clinical syndromes. Its discovery engine and clinical path offer the promise of redefining the pathogenesis and treatment of certain autoimmune diseases. I am delighted to join such a dedicated and innovative organization," said Dr. Van Parijs.

Prior to joining Alba, Dr. Van Parijs held senior level positions in clinical development (phases II-IV) and medical affairs at two multinational pharmaceutical companies. From 2003 to 2007, Dr. Van Parijs served as Senior Director, Clinical Development and Medical Affairs in the Infectious Diseases Center (Anti-Infectives) at GlaxoSmithKline (GSK) where she was responsible for directing the clinical sections of regulatory submissions, defining and implementing later phase clinical strategy for Anti-Infectives in the pipeline, and for medical affairs, including prom
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Sharon Ethanol appoints operations director
3. Kyron appoints former AMA chairman to board
4. Brady appoints GE efficiency expert as CTO
5. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
6. Johnson Controls appoints Roell to head EOC
7. SecurePipe appoints two senior execs
8. Milwaukees PointOne appoints new president and CEO
9. Third Wave appoints new chairman
10. Midwest Venture Summit disappoints; Cato grades Midwest governors
11. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...swire-USNewswire/ -- The Michael J. Fox Foundation...1.5 million in total awards to six research teams ...herapies for Parkinson,s disease. The funding was ...ery for Parkinson,s Disease program, made possibl...LN ), a neuroscience-based biotechnology company. ...
(Date:11/30/2009)...30 Biopharmaceutical company Kiadi...ave been enrolled in its,multinational registratio...ned to show reduction in transplant related mortal...tem cell transplantation with a mismatched,(haplo-... for an allogeneic,stem cell transplantation but w...
(Date:11/30/2009)... Novavax, Inc. (Nasdaq: ... in the Phase II clinical study of its trivalent s...VLP vaccine candidate in healthy adults 60 years o...ouble-blind, active-controlled study is comparing ... different doses (15 mcg and 60 mcg) of Novavax,s ...
(Date:11/30/2009)...RNewswire-FirstCall/ -- Cell Therapeutics, Inc. (C...s new class of platinum-based anti-tumor compounds...nti-tumor potency and activity compared to current...he ability to overcome cisplatin-resistance in can...aper titled "Novel Bis-platinum Complexes Endowed ...
Breaking Biology Technology:The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3
... CHICAGO Early this year, the ongoing saga of the...those of you who havent been following the news ov...ile bid by French pharmaceutical giant Sanofi-Syn... giant Aventis . , ,This would create a real maj...bined company would create the worlds third-larges...
... Madison, Wis. -- Pulling an all-nighter has never...sconsin-Madison Business School students who won...s Lang, Gail McGuire and Paul Pucci, all MBA stude...nture capitalists and a $100 cash prize. , ,The ne...ing, is designed to put students in the role of ve...
... Madison, Wis. -- Third Wave Technologies Inc , a...announced the release of its Invader 2D6 analysis ...with access to a broad range of pharmacogenetic as...panel is a pharmacogenetic testing solution that o...onfigure custom assay panels. The panel is being u...
Other Biology Technology:The Industry Impact of Two Big Pharmas Mating 2The Industry Impact of Two Big Pharmas Mating 3The Industry Impact of Two Big Pharmas Mating 4The Industry Impact of Two Big Pharmas Mating 5The Industry Impact of Two Big Pharmas Mating 6The Industry Impact of Two Big Pharmas Mating 7VC Contest Winners Learn from Experience 2Third Wave Releases Gene Test 2
(Date:11/26/2009)...hitehead researchers have developed a new type of ...c genes and proteins used by pathogens, according ...l cultures genes are present in two copies: one in...ene inactivation by mutation is therefore ineffici...nd copy usually remains active and takes over. , ...
(Date:11/26/2009)...ccus Aureus ) and other drug-resistant bacteria co...ototype devices have been developed to offer safe,... , Two prototype devices have been developed: on... hands and feet) in hospitals and public spaces wh... to shoot bacteria-killing agents into infested ch...
(Date:11/25/2009)...ach, may be used to boost resistance to, or slow, ...l of Medicine researchers report in a study publis...nce . , Parkinson,s disease is caused by a degen...rain known as the substantia nigra, which is respo...n of dopamine in late-stage Parkinson,s causes sym...
Breaking Biology News(10 mins):Knockouts in human cells point to pathogenic targets 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Hormone ghrelin can boost resistance to Parkinson's disease 2Whooping Cough Immunity Lasts 30 Years or More 60406 1Whooping Cough Immunity Lasts 30 Years or More 60406 2Scientist Throws Curve Into Breaking Ball Debate 60403 1Scientist Throws Curve Into Breaking Ball Debate 60403 2Scientist Throws Curve Into Breaking Ball Debate 60403 3Anesiva Announces Date for 2009 Annual Meeting of Stockholders to Vote on Proposed Merger 60400 1Anesiva Announces Date for 2009 Annual Meeting of Stockholders to Vote on Proposed Merger 60400 2Anesiva Announces Date for 2009 Annual Meeting of Stockholders to Vote on Proposed Merger 60400 3
...der, CO, USA - BULLETIN papers examine carbon-14...ests high ice-sheet sensitivity to small climate c...ied fossil forest in the Gold Hill Loess, Alaska; ... shrimp affect groundwater flow in the Biscayne aq... Appalachian Basin; and banded iron formations exp...
...rn microscopy technology has allowed two scorpion ...ity in Berlin and Lorenzo Prendini of the American...what is nearly invisible. Looking at tiny morpholo... outgrowths on lamellaestructures that fold like t...ory system its name, the book lungKamenz and Prend...
...SON, WI, JANUARY 12, 2009 - With recent increase i...nto alternative energy sources, the increased harv...ion is likely in the future. This may be especiall... in part because perennially high residue amounts ...ue left on the soil surface is a source of inoculu...
Other Biology News:January-February GSA Bulletin media highlights 2January-February GSA Bulletin media highlights 3January-February GSA Bulletin media highlights 4January-February GSA Bulletin media highlights 5January-February GSA Bulletin media highlights 6January-February GSA Bulletin media highlights 7January-February GSA Bulletin media highlights 8January-February GSA Bulletin media highlights 9January-February GSA Bulletin media highlights 10January-February GSA Bulletin media highlights 11Microscopic morphology adds to the scorpion family tree 2Microscopic morphology adds to the scorpion family tree 3Preventing soil erosion in continuous corn 2
Pyrex brand Fernback baffled culture flask from Sigma-Aldrich
... simple and efficient means for isolation of apopt...netic beads (MagBeads). Annexin V is a Ca2+-depend...y for phosphatidylseri The Apoptotic Cell Isolati...solation of apoptotic cells or removal of dead cel...
Xylene Cyanole FF from Sigma-Aldrich
...igned to be a solid, heavy-duty durable orbital sh...ng and vortexing in nature. The VSOS-4 Orbital ...uniform orbital shaking motion (19mm circular) for...ell/tissue culture, hybridization, staining and de...
Biology Products: